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Mutations of the spastin gene (Sp) are responsible for the most frequent autosomal dominant form of spastic
paraplegia, a disease characterized by the degeneration of corticospinal tracts. We show that a deletion in the
mouse Sp gene, generating a premature stop codon, is responsible for progressive axonal degeneration,
restricted to the central nervous system, leading to a late and mild motor defect. The degenerative process
is characterized by focal axonal swellings, associated with abnormal accumulation of organelles and cyto-
skeletal components. In culture, mutant cortical neurons showed normal viability and neurite density.
However, they develop neurite swellings associated with focal impairment of retrograde transport. These
defects occur near the growth cone, in a region characterized by the transition between stable microtubules
rich in detyrosinated a-tubulin and dynamic microtubules composed almost exclusively of tyrosinated
a-tubulin. Here, we show that the Sp mutation has a major impact on neurite maintenance and transport
both in vivo and in vitro. These results highlight the link between spastin and microtubule dynamics in
axons, but not in other neuronal compartments. In addition, it is the first description of a human neurodegen-
erative disease which involves this specialized region of the axon.
INTRODUCTION
Hereditary spastic paraplegia (HSP), or Strumpell–Lorrain
syndrome, is a heterogeneous group of inherited disorders of
the central nervous system, characterized by a slowly pro-
gressive bilateral spastic paraparesis. HSP may occur in
either a clinically pure form or associated with other symp-
toms such as dementia, extrapyramidal disturbance, optic
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neuropathy, cortical and cerebellar atrophy, peripheral neuro-
pathy or seizures. The core feature of the neuropathology is
pallor of the lateral corticospinal tracts. The dorsal columns
are also involved, particularly the fasciculus gracilis. The
spinal cerebellar tracts are variably affected. Loss of the
Betz cells of the motor cortex has occasionally been reported,
but motor neurons of anterior horns are generally spared. The
consistently distal pattern of involvement of the corticospinal
tracts and dorsal columns has led to the suggestion that the
pathology of HSP represents a dying back axonopathy.
HSP shows considerable genetic heterogeneity and can be
inherited as an autosomal dominant (AD-HSP), autosomal
recessive or X-linked recessive disorder (reviewed in 1).
Genes identified to date include spastin, spartin, kinesin
heavy chain (KIF5A), heat shock protein 60 (HSP60), atlastin,
paraplegin, L1 cell adhesion molecule (L1-CAM ), proteolipid
protein (PLP), NIP1A, Maspardin, BSCL2, ZFYVE27 and
REEP1 (reviewed in 2). The identification of genes respon-
sible for HSP highlighted the diversity of molecular defects
underlying HSP, including impairment of mitochondrial func-
tion (paraplegin and HSP60), failure of axonal transport
(kinesin heavy chain) or impairment of axoglial interaction
(L1-CAM and PLP).
The most prevalent form of AD-HSP (40%) is linked to the
SPG4 locus on chromosome 2p21, which encodes a novel
protein named spastin (3). Mutation analysis of the SPG4
locus has previously shown various DNA alterations of the
spastin gene including nonsense (15%), deletion (23%), inser-
tions (7.5%), splice site mutations (26.5%) or missense
mutations (28%; 4–10). It is likely that nonsense or splice
site mutations result in loss of function (11). However, some
spastin missense mutations could act as dominant negative
mutations (12). The spastin gene is ubiquitously expressed
and encodes a protein of 616 amino acids. Its C-terminus
shows significant homology to members of the AAA protein
family (ATPase associated with diverse cellular activities,
residues 376–505, 3 and 13). AAA proteins are involved in
a wide variety of functions including metalloprotease activity,
involvement in vesicle and organelle biogenesis, cell cycle
regulation, ribosome assembly in mitochondria or as
components of the 26S proteasome (13). The AAA ATPase
domain of spastin is homologous to katanin, a microtubule-
severing protein, suggesting a similar function for spastin. In
neurons, katanin appears to be a source of non-centrosomal
microtubules (14). Katanin overexpression in cultured
mammalian neurons alters process outgrowth (15), and
overexpression in D. Melanogaster results in developmental
abnormalities of the mushroom body (16). Interestingly,
Errico et al. (17). suggested a role for spastin in microtubule
dynamics in vitro. Wild-type spastin proteins, transfected
into neuronal and non-neuronal cells, interacted transiently
with microtubules, resulting in the disassembly of the micro-
tubules. This supports a role for spastin in microtubule sever-
ing. It is now clear that spastin is sufficient for microtubule
severing and several disease-associated mutations in spastin
abolish both ATPase and severing activities (18). In addition,
spastin contains a microtubule interacting and organelle trans-
port domain (MIT, residues 114–191) sharing homology with
spartin. Spartin mutations cause another inherited spastic para-
plegia associated with mental retardation (19). Other functions
of spastin have been suggested from the identification of spas-
tin’s partners using a variety of approaches. These include the
centrosomal protein NA14, CHMP1B, atlastin, Reticulon1 and
ZFYVE27, which are proteins involved in membrane traffic
events; however, these interactions remained to be confirmed
in vivo (17,20–23).
In order to elucidate the pathogenesis of HSP linked to
spastin mutation, loss-of-function models have been used.
When drosophila Dspastin was deleted, aberrantly stabilized
microtubule cytoskeleton in neurons was observed and
defects in synaptic growth and neurotransmission were also
detected (24). Recently, knock-down spastin function in zebra-
fish embryos resulted in dramatic defects in motor axon
growth during development (25).
HSP linked to spastin mutations affects mainly corti-
cospinal tracts without any involvement of the peripheral
nervous system. Therefore, the generation of an animal
model in higher organisms should contribute to refine the
HSP pathogenesis. To this end, we have generated mice carry-
ing a deletion of the Sp gene resulting in a frameshift and the
lack of the AAA domain through homologous recombination.
This mutation mimicks nonsense or frameshift mutations of
human Sp exon 5, which are found in 15% of HSP patients
and result in the absence of the AAA cassette (4). Mutant
mice develop a progressive axonopathy characterized by
focal swellings of axons without any loss of neurons. In
addition, marked accumulation of organelles and intermediate
filaments was observed within axonal swellings. Primary cul-
tures of cortical neurons derived from mutant embryos showed
normal viability and neurite outgrowth. However, they display
neurite swellings associated with an impaired retrograde trans-
port of organelles. These defects occur in a specialized region
of the neurite close to, but distinct from, the growth cone. This
region is characterized by the transition between a stable
microtubule domain rich in detyrosinated a-tubulin and a
dynamic one, composed almost exclusively of tyrosinated
a-tubulin. Our data highlight the link of spastin to microtubule
dynamics in axons, but not in other cell compartments.
RESULTS
Generation of mice carrying a heterozygous
or homozygous intragenic deletion of the spastin gene
leading to the lack of the AAA domain
To generate a mouse model of HSP, we used gene targeting in
murine embryonic stem cells to introduce a truncating
mutation into the spastin (Sp) gene through homologous
recombination. Because we wanted the mice to survive, we
used a targeting vector that includes loxP sequences in
introns 4 and 7. In intron 4, the NeoR gene was introduced
at the 30 end of the loxP sequence (Fig. 1A). Southern blot
analysis of embryonic stem cells confirmed homologous
recombination at the Sp locus (Fig. 1B). Mice heterozygous
or homozygous for the loxP-flanked Sp allele (SpF) appear
similar in size and morphology to wild-type mice. No alterna-
tive splicing of Sp exons or variation in transcript amount
was detected by RT–PCR amplification analysis of RNA
extracted from various tissues of the (SpF/F) or (SpF/þ) mice,
indicating that neither the NeoR gene nor the loxP sequences
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have a deleterious effect on spastin RNA splicing or transcrip-
tion (data not shown). Mice heterozygous for the SpF allele
were crossed to transgenic mice expressing the Cre recombi-
nase transgene under the control of the CMV promoter (26).
Cre recombinase expression in the germline led to the gener-
ation of mice carrying a heterozygous deletion of spastin
exons 5–7 (SpD/þ). (SpD/þ) mice gained weight normally
after birth and were fertile. They were maintained on a
C57BL6/J genetic background and then intercrossed.
Progeny carrying a heterozygous (SpD/þ) or homozygous
(SpD/D) deletion of Sp exons 5–7 in all cell types (Fig. 1C)
were observed, with the expected ratio for each genotype
(50 and 25%, respectively). (SpD/D) mice have a normal life
expectancy but were sterile. Truncated Sp transcripts lacking
exons 5–7 were detected in various tissues including brain
(Fig. 2A) and confirmed by sequence analysis of PCR
amplification products of reverse transcripts (Fig. 2B).
Alternative spliced products linking exons 4–8 were observed,
leading, as expected, to a frameshift and a stop codon 29 bp
after the exons 4–8 junction (Fig. 2B). This mutated protein
lacks the AAA cassette. Using rabbit polyclonal anti-
bodies (4828), which recognize an epitope of spastin located
within the deleted region, immunoblot analysis revealed the
full-length 60 kDa spastin in wild-type, but not (SpD/D) mice
(Fig. 2C).
Heterozygous or homozygous deletion of spastin
exons 5–7 results in progressive axonopathy of the
central nervous system
Semi-thin sections of the brain and spinal cord of
12-month-old mutant mice (SpD/D) did not reveal either disor-
ganization or developmental defects of the CNS (Online
Supplementary Material 1). We asked whether the degener-
ation of the spinal tracts, which occurs in the human
disease, also occurs in mutant mice. Transverse semi-thin sec-
tions of spinal cord were examined in 4- and 12-month-old
(SpD/D) mutant and (SpF/þ) or (Spþ/þ) control mice using
toluidine blue staining (three mice in each group). The organ-
ization of descending and ascending tracts was normal. In
4-month-old mutant mice (SpD/D), the striking feature was
the presence of axonal swellings in the white matter of the
spinal cord of mutant mice (1+ 0.5 and 4+ 0.5 SE axonal
swellings per spinal cord section at the lumbar and cervical
level, respectively; Fig. 3). We quantified the number of
axonal swellings in 12-month-old mutant mice (n ¼ 3) and
Figure 1. Mutagenesis of the murine spastin gene. (A) The panel shows the wild-type genomic spastin locus (wt), the targeting vector, the targeted locus (SpF)
and the Cre-mediated deleted locus (SpD). Filled rectangles indicate exons and arrowheads indicate the position of loxP sequences. The locations of the PCR
primers used to screen for the presence of targeted and deleted locus are shown. The DNA probe (indicated by asterisk) used to confirm the homologous recom-
bination is also given. (B) Southern blot analysis of DNA from wild-type (Spþ/þ) and (SpF/þ) ES cells. Digestion of DNA with EcoRI (EI) generates a 6.9 kb
wild-type and 8.7 kb ‘floxed’ fragments (SpF/þ) which are detected with a probe derived from Sp intron 4 (asterisk). (C) PCR amplification of the (Spþ), (SpF)
and (SpD) alleles from DNA of (Spþ/þ), (SpF/þ), (SpD/þ) and (SpD/D) mice using Spin4F, Spin7F and Spin7R primers. EI, EcoRI; B, BamHI; EV, EcoRV;
S, Sph1; Neo, neomycine resistance cassette gene.
3546 Human Molecular Genetics, 2006, Vol. 15, No. 24
found an increased number of axonal swellings with age,
which was more pronounced in the lumbar (7.3+ 1.7 SE,
7-fold increase, P ¼ 0.02) than in the cervical levels
(8+ 1.5 SE, 2-fold increase; Fig. 3F). Axonal swellings
were observed in both descending and ascending tracts of
the spinal cord. No axonal swellings were observed in
control (SpF/þ) or (Spþ/þ) mice at either 4 or 12 months of
age (n ¼ 3 in each group). In 24-month-old mutant mice,
numerous swelling axons with thin myelin sheaths were
observed, with dramatic disorganization of cytoskeletal com-
ponents in corticospinal tracts (Fig. 4H). These results show
a progressive axonal defect in mutant mice. To determine
the extent of axonal swellings, longitudinal semi-thin sections
of spinal cord were examined and axonal swellings were found
to be limited in length (Fig. 3E). In contrast, no change was
detected in the density or morphology of motor neuron cell
bodies, in either the motor cortex or spinal cord of 12- or
24-month-old homozygous mutant, when compared with
control mice (Online Supplementary Material 2). In addition,
no increased proportion of glial cells was observed in either
the motor cortex or spinal cord of mutant mice (data not
shown). These results indicate that the spastin mutation
results in a defect which is restricted to axons. To determine
whether this defect involves the peripheral nervous system,
transverse semi-thin sections of sciatic nerves were examined
in 12-month-old (SpD/D, n ¼ 3) mutant and (SpF/þ, n ¼ 3)
control mice. No axonal swelling was observed in the sciatic
nerve of 12-month-old mutant mice (Online Supplementary
Material 2) or in older mice (24 months of age, data not
shown), indicating that the axonal defect was restricted to
the central nervous system of mutant mice, similar to what
is found in human HSP linked to spastin mutations.
To determine whether the occurrence, or the number, of
axonal swellings correlated with a dose effect of wild-type
spastin allele, semi-thin sections of spinal cord from
12-month-old (SpD/þ) heterozygous mutant mice were ana-
lysed (n ¼ 3). Axonal swellings were observed in heterozy-
gous mice in both cervical and lumbar spinal tracts. At the
lumbar level of the spinal cord, the number of axonal swel-
lings was markedly lower in 12-month-old heterozygous
Figure 2. Analysis of spastin transcript and protein in control and mutant mice. (A) Transcript analysis of Sp from the brain of 2-month-old mice. RT–PCR
amplification of Sp was performed from total RNA using primers Slymph and ex12spas. RT–PCR amplification reveals the Sp transcripts retaining (900 bp)
or lacking exons 5–7 (500 bp). The abundance of full-length transcripts (Spþ) was evaluated by densitometric analysis of spastin and aldolase PCR products.
The ratio of spastin to aldolase expression was calculated, and then the relative amount of spastin in (SpF/þ) and (SpD/þ) tissues was expressed as a percent of
wild-type spastin level (Spþ/þ). (B) Sequence analysis of the RT–PCR products generated from the RNA of (Spþ/þ) and (SpD/D) mice. Arrows indicate the
boundaries of each exon and an asterisk shows the stop codon in exon 8. (C) Using rabbit polyclonal antibodies (4828), immunoblot analysis of spastin
shows the full-length 60 kDa spastin in brain of (SpF/þ) but not (SpD/D) mice. Note the half dose of spastin in (SpD/þ) mice. Actin was used as internal control.
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(0.7+ 0.3 SE, n ¼ 3) compared with homozygous mutant
mice (7.3+ 1.7 SE, n ¼ 3, 11-fold decrease, P ¼ 0.02;
Fig. 3G). Swellings were less frequent in the cervical spinal
cord of heterozygous mutant mice when compared with homo-
zygous mice (Fig. 3G). These data strongly suggest a dose
effect of wild-type spastin on the severity of the axonal defect.
The surfaces of non-swollen axons were then evaluated in
the corticospinal tract of 12-month-old mutant (SpD/D, n ¼ 3)
and compared with control mice (SpF/þ, n ¼ 3) to determine
whether the axonal swellings reflected a generalized axonal
defect. At least 450 axons were analysed in each mouse. Inter-
estingly, no difference was detected, suggesting that the
axonal swellings occur in specific regions of axons (Online
Supplementary Material 3).
Swollen axons contain an abnormal accumulation
of organelles and cytoskeletal components
To examine the content of axonal swellings, thin sections of
the spinal cords of 12-month-old homozygous mutant and
control mice were processed for electron microscopy.
Swollen axons, surrounded by a thin myelin sheath, contained
a large number of organelles including mitochondria, lyso-
somes and peroxysomes, associated with multilamellar dense
bodies and vacuoles (Fig. 4). In addition, abnormal accumu-
lation and disorganization of neurofilaments were observed.
In older mutant mice (24 months of age), marked depletion
of cytoskeletal components, including microtubules, was
noted in the axonal swellings (Fig. 4H).
To determine whether the abnormal accumulation of orga-
nelles was widespread in neuronal compartments, semi-thin
sections of motor cortex and anterior horns of the spinal
cord of 12-month-old homozygous mutant mice (n ¼ 3) and
control (n ¼ 3) were examined. Neither accumulation of orga-
nelles nor aggregates in the cytoplasm or nuclei of motor
neuron cell bodies were detected (Online Supplementary
Material 2).
These data indicated that the spastin mutation is responsible
for a progressive axonopathy, characterized by focal axonal
swellings associated with an accumulation of organelles,
suggesting an impairment of axonal transport. We then went
on to quantify the level of motor proteins involved in this
process, including dynein intermediate chain, p150 and p50
dynactin, kinesin light chain together with cytoskeletal com-
ponents including actin, neurofilament subunits and tyrosi-
nated (Tyr) and detyrosinated tubulins (Glu). Brain and
spinal cord extracts of 12- or 24-month-old homozygous
mutant and control mice were analysed by western blotting.
No difference in the amount of proteins was observed
(Online Supplementary Material 4; data not shown). These
data indicate that the defect of axonal transport, as suggested
by the massive accumulation of organelles, was not associated
with any obvious quantitative changes in motor proteins or in
cytoskeletal components. It was not unexpected, considering
the focal distribution and low frequency of axonal swellings
in mutant mice.
Motor function of spastin mutant mice
To determine whether mutant mice had impaired motor func-
tion, gait parameters were evaluated by footprint analysis of
4-, 12- and 22-month-old control (SpF/þ) and homozygous
Figure 3. Axonal swellings in spinal cord of mutant mice. (A–E) Toluidine blue staining of transverse (A–D) and longitudinal (E) semi-thin sections of spinal
cord from control (SpF/þ) (A and C) and mutant (SpD/D) (B, D and E) mice of 4- (A and B) and 12 months of age (C–E). Arrows show the axonal swellings on
transverse (B and D) or longitudinal sections (E). Scale bar: 20 mm (A–E). (F and G) Number of axonal swellings per spinal cord section. Asterisks indicate
statistically significant higher number of axonal swellings (P , 0.05) in 12-month-old when compared with 4-month-old mutant mice (SpD/D) (F) and in
12-month-old homozygous (SpD/D) when compared with heterozygous (SpD/þ) mutant mice (G). Cerv, cervical; Lumb, lumbar; m, month. Vertical bars indicate
standard error.
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mutant mice (SpD/D). The alternation coefficient, describing
the uniformity of step alternation and step length, revealed a
defect in both parameters in 22-month-old mutant mice
when compared with control (Fig. 5A). In addition,
examination of the critical speed (CS) (27), which reflects
aerobic motor capacity, showed a 35% decrease of the CS in
mutant mice from 15 to 24 months of age compared with
17% in control mice (P ¼ 0.04, Fig. 5B). In contrast,
evaluation of the spontaneous motor activity demonstrated a
frequency of slow and fast movements or rearing (vertical
activity), which was similar in homozygous mutant and
control mice (Fig. 5C). These data indicate that axonal
degeneration of the CNS results in a late and moderate
motor defect.
The Spastin mutation phenotypically gives rise to swellings
and impairment of retrograde transport in a specialized
region of the axon in primary cultures
We cultured (SpD/D), (SpD/þ) and (Spþ/þ) cortical neurons in
order to examine the neuronal phenotype in vitro. Cortical
neurons were collected from 14.5 days post-coitum embryos
(d.p.c.), plated and observed for six successive days. The via-
bility of cells was not affected by the SpD mutation, as defined
by the number of (SpD/D) mutant and (Spþ/þ) control neuronal
cells present 6 days after plating (Fig. 6A). In addition, vital
(trypan blue dye) or TUNEL staining did not reveal any differ-
ences between (Spþ/þ) control and mutant neurons (SpD/D)
(data not shown). Immunolabelling of phosphorylated heavy
subunit neurofilament or acetylated tubulin revealed that the
cortical neurons develop neurites upon differentiation. Six
days after plating, immunolabelling of neurofilaments, the
intermediate filament specific to neurons, was observed
in .99% of cells, indicating that neuronal cells were not con-
taminated by glial or other non-neuronal cell types. Consistent
with this result, immunolabelling with glial fibrillary acidic
protein (GFAP), which is a marker specific to astrocytes,
never revealed any positive cells (data not shown). The
density of neurites was evaluated in control (Spþ/þ) and hetero-
zygous (SpD/þ) and homozygous mutant cells (SpD/D), 1 or 6
days after cell plating. No difference in neurite density was
detected between mutant and control cells (Fig. 6B and C).
Although the immunolabelling of neurofilament or acetyl-
ated tubulin did not reveal any neurite defect 1 day after
plating, mutant cells did, however, develop neurite swellings
from day 4. They were characterized by focal swellings
located exclusively in distal regions of the neurites (Fig. 7).
They were not associated with neurite branching and were
close to, but distinct from, the growth cone, as determined
by immunolabelling of acetylated tubulin and actin (Fig. 8).
Six days after plating, the number of neurite swellings was
measured on acetylated tubulin immunolabelled neurons rela-
tive to 100 DAPI-stained nuclei. At least 1000 neurons per
embryo were analysed in control (Spþ/þ, n ¼ 3) heterozygous
(SpD/þ, n ¼ 4) and homozygous (SpD/D, n ¼ 3) mutant cells.
A mean of 3.86+ 0.001, 0.7+ 0.001 and 0.08+
0.003% neurite swellings were observed in (SpD/D), (SpD/þ)
and (Spþ/þ) cells, respectively (Figs 6D and 7). Similar
results were observed using a neurofilament specific
antibody (data not shown). These data demonstrate that
(SpD/D) neurons exhibit a marked increased frequency of
neurite swellings compared with heterozygous (SpD/þ) or
wild-type cells (Spþ/þ, P , 0.001 for each comparison), in
agreement with in vivo data. In addition, the data show that
a half dose of spastin is sufficient to attenuate the cellular
phenotype, suggesting a loss of function of the mutated
spastin. To further investigate this hypothesis, transfection
experiments of mutated spastin fused to GFP (GFP-SpD) or
GFP alone were performed on primary cultures of wild-type
cortical neurons (Spþ/þ). No neurite swellings were observed
in 1100 GFP-SpD positive neurons (Fig. 7). These data
indicate that overexpression of this mutation did not have a
dominant effect.
Interestingly, phase contrast analysis of neurite swellings
revealed an increased density of axoplasm in the proximal
Figure 4. Ultrastructural analysis of axonal swellings in the spinal cord of
mutant mice. Ultrathin sections of lumbar spinal cord of 12-month-old
control (SpF/þ) (A, C and E) and mutant mice (SpD/D) (B, D and F). Note
the axonal swelling (B) (asterisk) filled with organelles (D and F) (arrowheads)
and filaments (D) (arrow) in mutant spinal cord (B, D and F). In 24-month-old
mutant mice (H), dramatic disorganization of the axoplasm was observed in
swellings (asterisk) when compared with control of the same age (G). At
each age, three control and mutant mice were analysed. Scale bar: 2 mm (A,
B, G and H); 0.2 mm (C–F).
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part of the swellings (Figs 8B and 9A). To determine whether
this might reflect an impairment of axonal transport, mito-
chondria and peroxysome labelling was performed using
Mitotraker and anti-catalase antibody, respectively (Fig. 9).
Surprisingly, abnormal accumulation of both organelles was
observed in the proximal part of neurite swellings. In addition,
abnormal accumulation of peroxysomes was shown in the
growth cones downstream from swellings, further suggesting
a defect in retrograde axonal transport (Fig. 9). These orga-
nelles did not accumulate in other cell compartments. The
results strongly suggest a focal impairment of retrograde
transport of organelles in mutant neurons.
Neurite swellings occur in the distal region of the axon
that differs in composition and stability of microtubules
Surprisingly, neurite swellings were exclusively localized in
close proximity to, but distinct from, the growth cone
(Figs 7–9). The distance between the terminal portion of
neurite swellings and the end of the neurite, as determined
by immunolabelling of acetylated tubulin, was 20–100 mm.
Swellings were never associated with neurite branching.
Axons consist of stable and labile microtubule domains that
are distinguishable on the basis of their a-tubulin composition:
labile microtubules are rich in tyrosinated a-tubulin (Tyr),
whereas stable microtubules are rich in a-tubulin that has
been post-translationally detyrosinated and/or acetylated
(Glu) (28,29). In the distal region of the axon, contiguous
with the growth cone, there is an abrupt transition between a
proximal domain rich in stable microtubules (Glu-tubulin)
and a more distal domain almost exclusively composed of
dynamic microtubules (Tyr-tubulin). To determine whether
neurite swellings occurred closed to this transition, immunola-
belling of Tyr- and Glu-tubulins was performed in control and
mutant neurons in culture (Fig. 10). In the control, the most
distal part of the axon stained brightly for Tyr-tubulin. The
intensity of staining then gradually decreased, reaching a con-
stant level over the remaining portion of the axon. The same
control axons stained uniformly for Glu-tubulin all along
their length, except in the distal part of axons in which a dra-
matic decrease or no staining was observed (Fig. 10). In
mutant neurons, the transition between stable and dynamic
microtubules was also observed. In addition, no difference
in Tyr- or Glu-tubulin expression levels was observed
between control and mutant neurons (Online Supplementary
Material 4). In contrast, all neurite swellings were strikingly
localized proximal to the transition between stable and
dynamic microtubules (Fig. 10). Microtubules in the axonal swel-
ling were predominantly Glu, suggesting an additional stabiliz-
ation in this region. In contrast, microtubules in the distal part
of the axon, immediately after the swelling, were mainly
composed of Tyr-tubulin, indicating the dynamic property of
Figure 5. Analysis of motor behaviour. (A) Footprint analysis of 4-, 12- and 22-month-old control (SpF/þ) and mutant mice (SpD/D). The progression of the step
length and alternation coefficient is presented. Motor defect was detected in 22-month-old homozygous mutant mice when compared with control mice. (B) CS
was examined in 15- and 24-month-old control (SpF/þ) and mutant mice (SpD/D). The results are presented as the ratio of the CS at 24 months to that at 15 months
of age. A 35% decrease in the CS was observed in mutant mice from 15 to 24 months of age. (C) Spontaneous motor activity. Slow, fast movements and rearings
were evaluated in 3-, 12- and 24-month-old (SpF/þ) and (SpD/D) mice. The number of animals of each group is indicated below each graphic. Vertical bars indi-
cate standard error. Asterisks indicate P-value ,0.05 () or ,0.01 ().
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those polymers. No detectable defect was observed in other
cell compartments. These results indicate that the focal swel-
lings associated with an impaired retrograde transport of orga-
nelles occur in a specialized region of the axon which is
characterized by a rapid transition between a stable and
dynamic microtubule network (28,29).
DISCUSSION
In this study, we generated mice carrying a deletion of the
spastin gene leading to a premature stop codon, thereby
mimicking 15% of the Sp mutations found in HSP patients.
This mutation is responsible for focal axonal swellings associ-
ated with marked accumulations of organelles and intermedi-
ate filaments, which suggest an impairment of axonal transport
in vivo. The axonopathy is restricted to the central nervous
system. An increased frequency of axonal defects as well as
disorganization of cytoskeletal components in swollen axons
is observed with age.
In addition, focal axonal swellings were observed in both
descending and ascending tracts of the spinal cord, suggesting
that the defect is not restricted to the corticospinal tract. These
results, associated with the absence of a developmental defect
of the central nervous system, indicate that mutated spastin
is responsible for the degenerative process. Importantly, no
loss of motor neurons was observed even at the latest stage
(24 months of age), indicating that Sp mutations lead
exclusively to axonal disease. The mutation causes late and
moderate motor defect in mice, indicating that the axonal
degenerative process is slowly progressive, in agreement
with the late occurrence of symptoms in adult HSP patients
and the mild course of the disease.
Trotta et al. (24) have shown that loss of Dspastin results in
the accumulation of stabilized tubulin and defects in synaptic
growth and neurotransmission, whereas overexpression
reduced the number of stable microtubules. Consistent with
this, spastin-deficient zebrafish embryos exhibit a disordered
microtubule network (25). However, dramatically impaired
outgrowth of motor axons from the spinal cord was also
observed in these embryos, associated with aberrant position-
ing of branchio-motor neuron cell bodies. In contrast,
mutation of the Sp gene in human or mouse (this study)
causes neurodegeneration in adulthood. The severe phenotype
observed in zebrafish is likely to be caused by the complete
knock-out of Sp. In contrast, the majority of HSP patients
carry heterozygous mutations, most of them leading to loss
of function and, therefore, haploinsufficiency. It is also poss-
ible, however, that the difference in CNS motor organization
between zebrafish and higher organisms might account for
the distinct phenotype of the Sp mutation.
Primary cultures of cortical neurons derived from mutant Sp
embryos exhibit the same focal swellings of neurites associ-
ated with abnormal accumulation of organelles, including
Figure 6. Characteristics of cultured cortical neurons carrying a spastin mutation. (A) Cell viability was estimated from the mean number of nuclei per field 6
days after plating of primary cultures of cortical neurons. Wild-type (Spþ/þ) (n ¼ 3), heterozygous (SpD/þ) (n ¼ 4) and homozygous mutant embryos (SpD/D)
(n ¼ 3) were analysed. At least 10 fields were analysed per embryo. (B and C) Neurite density was examined 1 (B) and 6 days (C) after plating of cortical
neurons from wild-type (Spþ/þ) (n ¼ 3), heterozygous (SpD/þ) (n ¼ 3) and homozygous mutant embryos (SpD/D) (n ¼ 3). At least 180 nuclei were analysed
per embryo. (D) Frequency of neurite swellings was evaluated in primary cultures of cortical neurons 6 days after plating. Neurons were derived from wild-type
(Spþ/þ) (n ¼ 3), heterozygous (SpD/þ) (n ¼ 4) and homozygous mutant embryos (SpD/D) (n ¼ 3). The number of neurite swellings was much higher in homo-
zygous than in heterozygous or wild-type cells. Asterisks indicate statistically different numbers of neurite defects between heterozygous and wild-type cells
(P, 0.02) or between homozygous and heterozygous mutant or wild-type cells (P, 0.001). At least 1000 neurons were analysed per embryo. Vertical
bars indicate standard error.
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mitochondria and peroxysomes, as those found in the mutant
mice. The lack of glial cells in primary cultures of neurons indi-
cates that the neurite defect observed in mutant neurons is a cell
autonomous process and does not result from defective glial
cells, as previously described in other mouse models of
spastic paraplegia, such as PLP-deficient mice (30). In contrast,
the early occurrence of neurite swellings in spastin mutant cells
(from day 4 after plating) compared with the late onset of
axonal defects in spastin mutant mice in vivo could be due to
a putative protective effect of the cell environment on axonal
maintenance in vivo. Survival of mutant cortical neurons was
similar to that of controls, demonstrating that the spastin
mutation does not affect neuron survival, in agreement with
in vivo data and the human HSP disease phenotype. Interest-
ingly, neurite swellings are associated with an abnormal
accumulation of both mitochondria and peroxysomes in the
proximal part of swellings, suggesting a focal impairment of
retrograde transport of these organelles. The absence of orga-
nelle accumulation in other cell compartments both in vivo
and in vitro suggests that this axonal transport defect is
restricted to this specialized region of the axon. Further study
of axonal transport will help to elucidate whether this defect
is restricted to these organelles and represents a primary event
leading to progressive neurite swellings.
The most striking feature was the localization of neurite
swellings in a specialized region of the axon characterized
by the transition between stable and dynamic domains that
differ in the composition of post-translationally modified
tubulin subunits (28,29). One of these modifications, known
as the tyrosination cycle, involves the enzymatic cyclic
removal of the C-terminal tyrosine residue of the a-tubulin
chain by a (so far uncharacterized) tubulin carboxypeptidase
and the re-addition of a tyrosine residue at the same location
by tubulin-tyrosine-ligase (31,32). The tyrosination cycle gen-
erates two a-tubulin variants, intact tyrosinated tubulin (Tyr-
tubulin) and detyrosinated tubulin (Glu-tubulin), which lacks
the C-terminal tyrosine of a-tubulin. In cultured cells, Tyr-
tubulin is widely distributed in cytoplasmic microtubules,
whereas Glu-tubulin is enriched in stable microtubules exhi-
biting little dynamic behaviour (33–35). Here, we show that
the spastin mutation results in neurite swellings contiguous
with the transition between the stable and dynamic domain
of the axon located close to, but distinct from, the growth
cone. These results highlight the involvement of spastin in
microtubule dynamics and neurite homeostasis in a highly
specific region of the axon. Swellings are restricted to this
specialized region of axon, and this may explain their low fre-
quency. In addition, the difference in composition and stability
Figure 7. Neurite swellings of cortical neurons derived from mutant embryos. (A–F) Primary cultures of cortical neurons derived from wild-type (Spþ/þ)
(A and A0) and mutant 14 d.p.c embryos (SpD/D) (B–F) were immunolabelled with acetylated tubulin antibody (A–F) 6 days after plating. Nuclei were
stained with Dapi (A0 and B0). Note the presence of neurite swellings at low (arrows) (B and B0) or high magnification (C–F). (G–G0 0 0) Transfection experiment
of wild-type cortical neurons with mutant spastin fused to GFP (GFP-SpD). GFP expression (G), immunolabelling of acetylated tubulin (G0), acetylated tubulin
and Dapi (G0 0) or GFP (G0 0 0). Note the absence of neurite swellings in transfected neurons. Scale bar: (A–B0 and G–G0 0 0) 50 mm; (C–F), 25 mm.
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of microtubules in this critical region could provide an expla-
nation for the focal distribution of defects along the length of
axons.
These data strongly suggest an important role of spastin in
the regulation of microtubule stability. Recently, using puri-
fied components, Evans et al. (18) have shown that spastin
interacts directly with microtubules and is sufficient for micro-
tubule severing. Several mutations, including missense
mutations in amino acids that are conserved in the AAA
domain and including Walker A and B motifs of the AAA
module, disrupt this activity (18). These mutations prevent
ATP binding or allow ATP binding but prevent hydrolysis,
thereby significantly eliminating ATPase activity. Thus, the
AAA domain, deleted in our mutant mice, is involved in
ATPase activity which is required for microtubule severing.
Microtubule severing occurs in the cell body of the neuron
(15), at sites of axonal branch formation (36) and within the
growth cones (37). Although the specialized region of the
axon in which neurite swellings occur in response to a
spastin mutation has been previously shown to differ in the
composition and stability of its microtubules, little is known
about microtubule severing in this region. In addition, an
important question is whether spastin acts directly on tubulin
composition within this specialized region. Transfection
experiments of wild-type spastin fused to GFP were per-
formed in the NSC34 neuronal cell line (38), and primary
culture of wild-type cortical neurons revealed the presence
of spastin in both cytoplasm and neurites (Online Supple-
mentary Material 5). Spastin was enriched in discrete regions
in neurites, in a pattern similar to that described in immorta-
lized neuron cell lines (17). The subcellular localization of
spastin in neurites is therefore consistent with a possible
direct role of spastin in the transition between stable and
labile microtubule domains in the axon. Further studies are
clearly required to define the localization and the role of
spastin in the regulation of microtubule dynamics in this
highly specialized region of the axon and to ascertain the
link with axonal transport. During bidirectional transport of
molecules or organelles, the net direction of axonal transport
is determined by the balance of plus- and minus-end motors.
Kinesins are plus-end-directed microtubule motors, whereas
dynein is a minus-end-directed microtubule motor (39). In
mutant neurons, an abnormal change in microtubule dynamics
could lead to a defective interaction of dynein with plus-end
microtubules, resulting in a focal defect of retrograde transport.
Interestingly, both in vivo and in vitro data demonstrate that
homozygous mutations resulted in a more severe phenotype
than heterozygous mutations, which strongly suggests a hap-
loinsufficiency mechanism underlying spastin-associated HSP.
The lack of neurite swellings in wild-type neurons transfected
with mutant spastin further supports a loss of function, rather
than a dominant effect, as the mechanism underlying HSP.
Figure 8. Neurite swellings of mutant cortical neurons are localized closed to the growth cone. Primary cultures of cortical neurons derived from wild-type
(Spþ/þ) (A, C and C0) and mutant 14 d.p.c embryos (SpD/D) (B, D and D0) 6 days after plating. Phase contrast demonstrates both the growth cone (arrowhead)
and neurite swelling (arrow) in mutant neurons (B). Note the increased density of neurite swelling content in the proximal part of axon. Immunolabelling of
acetylated tubulin (green) (C, C0, D and D0) and actin (phalloidin in red) (C0 and D0) confirms the close proximity of the neurite swelling to the growth
cone. Scale bar: 10 mm.
Human Molecular Genetics, 2006, Vol. 15, No. 24 3553
These results are in agreement with recent in vitro data showing
that several disease-associated mutations in spastin abolished
both ATPase and microtubule-severing activities (18).
In spite of the evidence for their involvement in distinct pro-
cesses, mutations of paraplegin, PLP, KIF5A or spastin (this
study) all lead to axonal degeneration and transport defect
(30,40,41). These data strongly suggest that axonal transport
defect is an important mechanism underlying the pathogenesis
of HSP. Axonopathy and alteration of axonal transport have
been suggested in various other neurodegenerative disorders
including Alzheimer’s disease (42). However, here we show
that the spastin mutation leads to axonal defects and alteration
of axonal transport of organelles restricted to a specialized
region of the axon close to its tip. This study is the first
description of a human neurodegenerative disorder triggering
this highly specialized region of the axon, both in vivo and
in vitro. It will be of interest to determine whether the
degenerative process starting from this critical region of the
axon is specific to the spastin mutation or also occurs in
other neurodegenerative disorders. Further study on the com-
position and the regulation of microtubule dynamics in this
region of the axon will be a starting point for the development
of therapeutics for HSP.
MATERIAL AND METHODS
Gene targeting and generation of mice
A 10.5 kb mouse genomic BAC-derived DNA fragment con-
taining spastin exons 5–7 was cloned into pcDNA 2.1. The
LoxP sequences were inserted into introns 4 and 7 in Sph1
and EcoRV restriction sites, respectively. Two recombinant
ES clones (clones C3 and C4) were selected. Mice harbouring
the targeted allele were identified by genotype analysis using
Figure 9. Accumulation of mitochondria and peroxysomes in the proximal region of neurite swellings. Primary cultures of cortical neurons derived from mutant
embryos 6 days after plating (SpD/D). Phase contrast (A and A0), immunolabelling of acetylated tubulin (green) (A0 0, B, B0 0, C and C0 0), mitotraker (A0, B0 and B0 0)
and catalase (C0 and C0 0) are shown. Note the increased density of neurite swelling (A and A0) associated with the accumulation of mitochondria (arrow) (B0 and
B0 0) and peroxysomes (C0 and C0 0) in the proximal part of the axonal swelling. (A0, B0 0 and C0 0) are merged images. Scale bar: 10 mm.
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primers spin7R (50-GCCATACAATCTATGGACTTCCA-30)
and spin7F (50-CTACACAGAGAAACCCA GTCTTG-30) to
reveal Spþ (190 bp) or SpF (340 bp) alleles. The (CMV-Cre)
transgenic line (26) was used to induce spastin deletion.
Mice carrying a heterozygous deletion of spastin exons 5–7
(SpD/þ) in all cell types were generated and intercrossed.
The truncated gene was detected by using primers spin7R
and spin4F (50-TGACTCCGTCATTG AGACCTGTA-30,
850 bp). Total RNAs were isolated using Trizol (Invitrogen).
cDNAs were amplified by PCR using primers Slymph
(50-TGACTAATTTGGTAATCCAG-30) and ex12spas
(50-CCC ATT ACA AGT ACT CTG TC-30) and sequenced.
(Spþ), (SpF/þ), (SpD/þ) and (SpD/D) mice were maintained on
the same genetic background (C57BL6J). The level of
Figure 10. Neurite swellings are located at the transition between stable and labile microtubule domains. Primary culture of cortical neurons derived from control
(Spþ/þ) (A–A0 0) and mutant embryos (SpD/D) (B–D0 0). Immunolabelling of Tyr-tubulin (A, B, C and D) and Glu-tubulin (A0, B0, C0 and D0). At the tip of axons,
Tyr-tubulin is solely expressed, whereas in the other regions of axons, both tubulins are expressed in either control or mutant neurons. In mutant neurons, note
that the neurite swellings are always localized proximal to the transition between labile (distal) and stable microtubule regions. Merged images (A00, B00, C00
and D00). Scale bar: 10 mm.
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spastin transcripts was evaluated using the quantity one
software (Biorad) in (Spþ/þ), (SpF/þ), (SpF/F), (SpD/þ) and
(SpD/D) mice (three mice in each group). All animal pro-
cedures were performed in accordance with institutional
guidelines (agreement B91-228-2 and 3429).
Generation of spastin antibodies and plasmid constructs
Rabbit spastin-specific antibodies were generated against a
synthetic peptide located within the deleted region (residues
116–250, Eurogentec, Belgium). NSC-34 cells (38) were tran-
siently transfected with GFP-Spþ or GFP-SpD constructs (see
subsequently and Online Supplementary Material 6). Immuno-
blotting of protein extracts was performed using anti-Sp rabbit
antiserum (4828, 1:10 000) or anti-GFP (1:8000, Molecular
probes). Spastin constructs were generated by PCR amplifica-
tion of the spastin coding region from the I.M.A.G.E. Consor-
tium Clone 6441742 (43). The resulting fragment was then
subcloned in frame into the eukaryotic expression vector
pcx-lGN, which contains GFP at the 5’ end (GFP-Spþ). The
deleted-spastin construct (GFP-SpD) composed of exons
1–4 fused to exon 8 was generated by PCR amplification.
Sequencing confirmed the integrity of coding regions of
both constructs.
Western blot analysis
Immunoblots were performed from total protein extracts of the
brain and spinal cord from 12- or 24-month-old control (SpF/þ,
n ¼ 3) and mutant mice (SpD/D, n ¼ 3). Immunoblotting was
performed using polyclonal antibodies anti-spastin (4828,
1:10 000), kinesin light chain (1:500, Santa Cruz Biotechnol-
ogy), NF68 (1:20 000, Chemicon) or mouse monoclonal
antibodies anti-actin (1:10 000, Sigma), p50 dynactin
(1:2000, Transduction Laboratories), p150 glued (1:20 000,
Transduction Laboratories), dynein intermediate chain (DIC,
1:2000, Chemicon), a-tubulin (1:5000, Chemicon),
phospho-NF200 (1:15 000, Chemicon), anti-NF160
(1:40 000, Chemicon), Tyr-a-tubulin (clone YL1/2,
1:50 000, kindly provided by D. Job), Glu-a-tubulin
(1:800 000, kindly provided by D. Job) and g-enolase
(1:20 000, kindly provided by A. Keller). Immunoblot analysis
of Tyr-, Glu-tubulins and actin was performed from total
protein extracts of primary cultures of cortical neurons from
control (Spþ/þ, n ¼ 3) and mutant mice (SpD/D, n ¼ 3).
Histological and ultrastructural analyses
Mice were anaesthetized and processed as previously
described (44). Semi-thin transverse sections (0.5 mm) were
stained with toluidine blue and examined under a Zeiss Axio-
phot microscope. Ultrathin sections were stained with uranyl
acetate and lead citrate and examined with a Tecnai F20 trans-
mission electron microscope (Philips), operating at 200 kV.
Axonal surface was assessed from electron micrographs of
randomly selected transverse thin sections of lumbar spinal
cord using the quantity one software (Biorad). Density of
neurons was evaluated on toluidine blue-stained transverse
sections of the motor cortex and the anterior horns of the
spinal cord.
Primary culture of cortical neurons
Primary cultures of cortical neurons were prepared from 14
d.p.c. embryos. The cortices of embryos were dissected in
Mg2þ, Ca2þ-free HBSS. Tissues were initially dissociated
by trypsin, mechanically dissociated by repeated triturations,
washed and then spun through a BSA cushion. Cortical
neurons were plated on poly-D-ornithine (5 mg/ml) and
laminin (2 mg/ml) coated dishes at a density of 9.3  104
cells/cm2 in Neurobasal medium (Invitrogen) plus B27
supplement. Cells were maintained for 6 days at 378C in 5%
CO2. Cultured cortical neurons were processed for immuno-
fluorescent staining of microtubules (acetylated tubulin,
1:10 000, Sigma), neurofilament (SMI31, 1:500, Chemicon),
GFAP (1:100, Sigma), catalase (1:100, Rockland), actin (rho-
damine phalloidin, 1:200, Molecular Probes), mitochondria
(Mitotraker Orange CM-H2TMRos, 150 nM, Molecular
Probes), Tyr- and Glu-tubulins (1:6000 and 1:3000, respect-
ively). Transfection experiments were performed using the
Nucleofector apparatus (Amaxa Biosystems) using 1–4 mg
of DNA (pcx-lGN, GFP-Spþ or GFP-SpD). Neurite outgrowth
assessment was performed using a stereological method, as
previously described by Ronn et al. (45).
Behavioural testing
Spontaneous motor activity. Mice were placed in a cage with
infrared beams at two levels in order to detect horizontal and
vertical mouse movements. The number of times the mice
crossed the infrared beams during a night period of 12 h was
recorded. Mice were studied from 3 to 24 months of age.
Footprint analysis. After coating the hind feet with non-toxic
ink, mice were allowed to walk through a tunnel (50 cm
length, 9 cm wide and 6 cm high) with paper lining the
floor. The footprint pattern generated was scored for several
parameters as previously described (46). Data were analysed
using an unpaired t-test.
Evaluation of the CS. CS is an index of the aerobic motor
capacity, based on the hyperbolic relationship between speed
and time to fatigue in individuals performing exhaustive
runs at different speeds. The protocol consisted of a run
once a day on a 10.6  30 cm treadmill (LE 8709, Bioseb,
Chaville, France) at constant speed leading to exhaustion as
previously described (27). This trial was repeated four con-
secutive days at a different speed. The time the mice were
able to run was recorded at each speed and was arbitrarily
limited to 40 min or exhaustion as defined by a total number
of 20 shocks. The CS was calculated from the slope of the
regression line, plotting the distance versus the time to exhaus-
tion for the four runs. In our study, the CS was measured in
four homozygous mutant (SpD/D) and three control mice
(SpF/þ) at 15 and 24 months.
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